According to a new market
report published by Transparency Market Research "Deep Brain Stimulation Devices Market for Parkinson's Disease
(North America, Europe, Asia-Pacific and Latin America)-
Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,"
the global deep brain stimulation devices market was valued at USD 4.5
billion in 2012 and is expected to grow at a CAGR of 11.0% from 2013 to
2019, to reach an estimated value of USD 9.4 billion in 2019.
Browse Global Deep Brain Stimulation Devices Market Report with Full TOC at http://www.transparencymarketresearch.com/deep-brain-stimulator-market.html
Rising number of
neurological disorders such ischemic stroke, Alzheimer's disease, essential
tremors, trauma and especially Parkinsonism are primary factors responsible for
the growth of deep brain stimulation devices market. Parkinson's disease is the
second most common chronic and progressive neurodegenerative disorder
characterized by postural instability, bradykinesia, akinesia and tremors due
to loss of dopamine producing neurons in substantia nigra of mid-brain.
In addition, rise in
geriatric population along with augmented demand for minimally invasive
surgical techniques have boosted the overall growth of this market. Moreover,
increase in preference of patients and healthcare professionals to adopt
surgical DBS devices over drug therapy owing to its significantside effects and
lack of effectiveness is further expected to drive the market in coming years.
Get Free Sample
Report at http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1435
According to the
Parkinson's DiseaseFoundation (PDF), it has been estimated that approximately
10 million people worldwide and one million Americans are living with
Parkinson's disease. Among these, in U.S. approximately 60,000 people are
diagnosed with Parkinson's disease each year. There are different treatment
options available for Parkinson's disease that include drug therapy, surgical
therapy, physical therapy and stem cell therapy. However, DBS surgical therapy
is mostly preferred in advanced stages of the disease while in early stages
chemotherapy is used.
Browse
all Medical Devices Market Research Reports at http://www.transparencymarketresearch.com/medical-devices-market-reports-6.html
The global deep brain stimulation devices market is
segmented geographically into North
America, Europe, Asia-Pacific andLatin America. Among
these, North America accounts for the largest market share of deep
brain stimulation devices market and is valued to be more than USD
2billion in 2012 owing to rise in number of patients who are adopting
surgical therapy for Parkinson's disease and rise in geriatric population. In
addition, favorable government reimbursement policies and growing side effects
from medication treatment are further expected toboost the growth of the market
in this region. The market for North America is followed
by Europe, Latin America and Asia-Pacific. Contributing
factors for the lowest market share of deep brain stimulation devices
in Asia-Pacific include lack of favorable government insurance policies
and high cost for surgical treatment.
Browse Blog at http://tmrresearch.wordpress.com/
The major players of this market include
Medtronic, Inc., St. Jude Medical, Inc. and Boston Scientific Corporation.
Other companies active in this market include Sapiens Neuro, Aleva
Neurotherapeutics SA, ANM Adaptive Neuromodulation GmbH, Synaptix, Neurosigma,
Inc. and Neurospace. The DBS products of these "Other" players are
not yet commercially available in the market since they are still under
clinical trials. Companies are heavily focusing on introducing innovative
products that are easy to use for physicians as well as patients. These
companies are also aiming to make them more portable.
No comments:
Post a Comment